A composition for controlling appetite and enhancing satiety and uses thereof

Abstract

The application discloses a composition for controlling appetite and enhancing satiety and application thereof, and belongs to the technical field of food; the composition for controlling appetite and enhancing satiety provided by the application comprises 10-30 parts of sodium carboxymethyl cellulose, 4-15 parts of polypeptide and 1-5 parts of fructus hoveniae powder; the polypeptide comprises at least one of whey protein peptide, casein hydrolysis peptide and collagen protein peptide. The application is compounded by selecting components in a specific mass fraction range, the components have a good synergistic effect, can effectively promote the secretion of GLP-1, inhibit the enzyme activity of DPP-4 and thus slow down the degradation rate of GLP-1, thereby prolonging the action time of the satiety signal; meanwhile, the composition can also increase the volume of gastric contents by water absorption and swelling, and provide physical satiety; thereby, the composition can synergistically achieve the appetite control for non-treatment purposes.

Description

Technical Field

[0001] This invention belongs to the field of food technology, and in particular relates to a composition for controlling appetite and enhancing satiety, and its application. Background Technology

[0002] As people become more health-conscious, consumers are increasingly demanding weight management products. Controlling appetite and increasing satiety to reduce energy intake is one of the important strategies for weight management.

[0003] In recent years, weight-loss drugs such as semaglutide, which have become popular in the weight management market, achieve weight loss by suppressing appetite. While semaglutide and other appetite-suppressing drugs have significant weight-loss effects, they also cause adverse reactions such as gastrointestinal discomfort, nausea, and headaches, and are relatively expensive. Compared to drugs, functional foods that control appetite are a relatively safe and lower-cost option. However, existing appetite-suppressing technologies in the food industry suffer from problems such as insignificant appetite-suppressing effects, unclear mechanisms of action, or single pathways of action. Some technologies that prolong the time food stays in the stomach due to its indigestible properties also cause gastrointestinal discomfort and insufficient nutrient absorption. For example, patent WO2026002161A1 uses carboxymethyl cellulose and silica-reinforced physically cross-linked hydrogels to achieve a feeling of fullness by occupying a high density in the stomach. Patent application number 202011288220.0, "A Meal Replacement Powder with a Feeling of Fullness and Its Preparation Method," uses konjac gum and carrageenan as main ingredients, and produces a feeling of fullness by prolonging gastric emptying time and increasing gastric retention time. Patent CN113975335B, "A Composition for Controlling Appetite and Inducing Satiety," achieves satiety control by inducing GLP-1 secretion through green coffee bean extract, hibiscus extract, and crocin.

[0004] However, the aforementioned existing technologies have problems in controlling weight and enhancing satiety, such as a single mechanism of action, weak satiety, easy to cause gastrointestinal discomfort, and poor nutrient absorption. Summary of the Invention

[0005] The purpose of this invention is to overcome the shortcomings of the prior art and provide a composition and its application that has a clear mechanism of action and multiple pathways working synergistically. Specifically, it can effectively promote GLP-1 secretion, inhibit DPP-4 enzyme activity, and absorb water to increase the content of gastric contents, thereby effectively controlling appetite and enhancing satiety.

[0006] To achieve the above objectives, in a first aspect, the present invention provides a composition for controlling appetite and enhancing satiety, the composition comprising the following components in parts by weight: 10-30 parts sodium carboxymethyl cellulose, 4-15 parts polypeptide, 1-5 parts Japanese raisin tree powder; The polypeptide includes at least one of whey protein peptide, casein hydrolysate peptide, and collagen peptide.

[0007] This invention has discovered that a compounding of sodium carboxymethyl cellulose, polypeptides, and Hovenia dulcis powder within a specific mass fraction range exhibits a good synergistic effect. It not only effectively promotes GLP-1 secretion and inhibits DPP-4 enzyme activity, thereby slowing down the degradation rate of GLP-1 and prolonging the duration of the satiety signal, but also increases the volume of gastric contents through water absorption and swelling, providing a physical feeling of fullness. In other words, the components within the specific mass fraction range provided by this invention can synergistically achieve non-therapeutic appetite control and weight management. Furthermore, when using the composition provided by this invention to achieve non-therapeutic appetite control and weight management, adverse reactions such as gastrointestinal discomfort are rarely observed.

[0008] Specifically, firstly, sodium carboxymethyl cellulose is a high-molecular-weight dietary fiber with extremely strong water absorption and retention capabilities. Upon entering the stomach, it rapidly absorbs water and swells, forming a gel-like substance with a certain viscosity, directly increasing the volume of stomach contents. Furthermore, this physical expansion of the stomach stimulates mechanoreceptors in the stomach wall, sending a "fullness" signal to the brain via the vagus nerve, thereby enhancing the feeling of satiety and reducing subsequent food intake. Simultaneously, the viscous environment created by the addition of sodium carboxymethyl cellulose not only slows gastric emptying, allowing the aforementioned physical feeling of fullness to last longer, but also, to a certain extent, encapsulates other components, delaying their release, thus prolonging the effect of the composition.

[0009] Secondly, Hovenia dulcis seeds are a food and medicine source. Besides their well-known hangover-relieving properties, they also contain dihydromyricetin, fruit acids, amino acids, and various trace elements, offering potential for even more beneficial effects. The active ingredients in Hovenia dulcis seed powder, along with whey protein peptides, casein hydrolyzed peptides, and collagen peptides, all have a certain effect on promoting GLP-1 secretion and inhibiting DPP-4 enzyme activity, thus prolonging the duration of satiety signals at the hormonal level. Furthermore, the addition of sodium carboxymethyl cellulose can achieve a more lasting and effective appetite control effect.

[0010] As a preferred embodiment of the composition of the present invention, the composition comprises the following components in parts by weight: 15-25 parts sodium carboxymethyl cellulose, 8-12 parts polypeptide, and 2-4 parts Hovenia dulcis powder.

[0011] The present invention has found that the mass fraction of the components in the composition affects the compounding effect between the components. When the mass fraction of the components is further selected within the above range, the overall performance of the obtained product is better.

[0012] In a preferred embodiment of the composition of the present invention, the polypeptide includes whey protein peptide, casein hydrolyzed peptide and collagen peptide; the mass ratio of the whey protein peptide, casein hydrolyzed peptide and collagen peptide is 1:(0.2-0.8):(0.2-0.8).

[0013] For example, the mass ratio of whey protein peptides, casein hydrolysate peptides, and collagen peptides can be any point value or a range between any two points between 1:(0.2-0.8):(0.2-0.8), such as 1:0.2:0.2, 1:0.2:0.4, 1:0.2:0.6, 1:0.2:0.8, 1:0.4:0.2, 1:0.4:0.4, 1:0.4:0.6, 1:0.4:0.8, 1:0.6:0.2, 1:0.6:0.4, 1:0.6:0.6, 1:0.6:0.8, 1:0.8:0.2, 1:0.8:0.4, 1:0.8:0.6, 1:0.8:0.8, etc.

[0014] In a preferred embodiment of the composition of the present invention, the mass ratio of whey protein peptides, casein hydrolysate peptides, and collagen peptides is 1:(0.6-0.8):(0.6-0.8). For example, it can be 1:0.6:0.7, 1:0.7:0.6, 1:0.7:0.7, 1:0.7:0.8, etc.

[0015] The present invention has found that the type of peptide affects the composition's effect on GLP-1 secretion and its inhibitory effect on DPP-4 enzyme. When the peptides are further selected to include whey protein peptides, casein hydrolysate peptides and collagen peptides, especially when the mass ratio of the three is within the above range, the resulting composition has a better promoting effect on GLP-1 secretion and a stronger inhibitory effect on DPP-4 enzyme activity.

[0016] As a preferred embodiment of the composition of the present invention, the viscosity of the 1wt% aqueous solution of sodium carboxymethyl cellulose is 1000-2400 mPa·s.

[0017] As a preferred embodiment of the composition of the present invention, the viscosity of the 1wt% aqueous solution of sodium carboxymethyl cellulose is 1200-2400 mPa·s.

[0018] For example, the viscosity of the 1 wt% aqueous solution of sodium carboxymethyl cellulose can be any point value or a range between any two points between 1200 and 2400 mPa·s, such as 1200 mPa·s, 1400 mPa·s, 1600 mPa·s, 1800 mPa·s, 2000 mPa·s, 2200 mPa·s, 2400 mPa·s, etc.

[0019] It should be noted that the viscosity test method for the sodium carboxymethyl cellulose is as follows: the test is conducted in accordance with GB 1886.232-2016, and the viscometer used is LVDV.

[0020] This invention has found that the viscosity and viscosity-average molecular weight of sodium carboxymethyl cellulose are positively correlated. The viscosity of sodium carboxymethyl cellulose affects its water absorption and swelling, resulting in different effects on the increase of gastric contents volume. At the same time, it also affects the overall viscosity, thereby affecting the gastric emptying rate and thus the residence time of other components in the stomach. In addition, its viscosity also affects the coating effect on other components, thereby affecting the release rate of other components and thus affecting the duration of satiety.

[0021] As a preferred embodiment of the composition of the present invention, the particle size of the Hovenia dulcis powder is 95%-100% passing through an 80-mesh sieve.

[0022] It should be noted that the particle size test method for the Hovenia dulcis powder is as follows: the test is performed in accordance with the second method 1 (1) of General Chapter 0982 of Part IV of the Chinese Pharmacopoeia 2020.

[0023] The present invention has found that the particle size of Hovenia dulcis powder affects the dispersion uniformity of the composition, as well as its dissolution performance and bioavailability, thereby affecting the effects on GLP-1 and DPP-4; when the particle size of Hovenia dulcis powder is further selected within the above range, the effects of controlling appetite and enhancing satiety are better.

[0024] As a preferred embodiment of the composition of the present invention, the whey protein peptides have an average molecular weight of 500-2500 Da.

[0025] As a preferred embodiment of the composition of the present invention, the whey protein peptides have an average molecular weight of 500-2000 Da.

[0026] For example, the average molecular weight of the whey protein peptide can be any point value between 500-2000 Da or a range between any two points, such as 500 Da, 800 Da, 1000 Da, 1200 Da, 1400 Da, 1600 Da, 1800 Da, 2000 Da, etc.

[0027] It should be noted that the average molecular weight of the whey protein peptides is determined by referring to GB / T 22492-2008.

[0028] As a preferred embodiment of the composition of the present invention, the proportion of peptides with a relative molecular mass ≤10 kDa of the casein hydrolysate is 65%-100%.

[0029] As a preferred embodiment of the composition of the present invention, the proportion of peptides with a relative molecular mass ≤10 kDa of the casein hydrolysate is 65%-90%.

[0030] For example, the proportion of peptides with a relative molecular mass ≤10 kDa of the casein hydrolysate peptide can be any point value or any range between two points between 65% and 90%, such as 65%, 70%, 75%, 80%, 85%, 90%, etc.

[0031] It should be noted that the test method for the relative molecular mass of the casein hydrolysate peptide is as follows: the test is performed in accordance with GB / T22492-2008.

[0032] In a preferred embodiment of the composition of the present invention, the collagen peptides have an average molecular weight of 800-3600 Da.

[0033] In a preferred embodiment of the composition of the present invention, the collagen peptides have an average molecular weight of 800-3000 Da.

[0034] For example, the average molecular weight of the collagen peptide can be any point value between 800-3000 Da or a range between any two points, such as 800 Da, 1000 Da, 1200 Da, 1500 Da, 1800 Da, 2000 Da, 2200 Da, 2500 Da, 2800 Da, 3000 Da, etc.

[0035] It should be noted that the average molecular weight of the collagen peptides is determined by referring to GB 31645-2018.

[0036] This invention has found that the average molecular weight of whey protein peptides, the proportion of peptides with a relative molecular mass ≤10 kDa of casein hydrolysate peptides, and the average molecular weight of collagen peptides affect their activity against GLP-1 and DPP-4. When the average molecular weight of whey protein peptides, the proportion of peptides with a relative molecular mass ≤10 kDa of casein hydrolysate peptides, and the average molecular weight of collagen peptides are further selected to be within the above-mentioned ranges, it is possible to better promote the secretion of GLP-1 and reduce the activity of DPP-4 enzymes.

[0037] In a second aspect, the present invention provides a method for preparing the composition of the present invention, wherein the preparation method comprises: mixing the components uniformly to obtain the composition.

[0038] Compared with the prior art, the beneficial effects of the present invention are as follows: This invention has discovered that a compounding of sodium carboxymethyl cellulose, polypeptides, and Hovenia dulcis powder within a specific mass range exhibits excellent synergistic effects. It not only effectively promotes GLP-1 secretion and inhibits DPP-4 enzyme activity, thereby slowing the degradation rate of GLP-1 and prolonging the duration of satiety signals, but also increases gastric contents volume through water absorption and expansion, providing a physical feeling of fullness. Furthermore, it causes extremely low rates of adverse reactions such as gastrointestinal discomfort. In other words, the components within the specific mass range provided by this invention can synergistically achieve non-therapeutic appetite control and weight management. Detailed Implementation

[0039] To better illustrate the purpose, technical solution, and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0040] Unless otherwise specified, the reagents, methods and equipment used in this invention are all conventional reagents, methods and equipment in the field; and unless otherwise specified, the raw materials used in parallel experiments are from the same batch.

[0041] The viscosity of a 1:1 wt% sodium carboxymethyl cellulose aqueous solution is 1816 mPa·s. It was purchased from Changshu Weiyi Technology Co., Ltd., product number 2024-12-292. The viscosity of the sodium carboxymethyl cellulose 2:1 wt% aqueous solution was 1000 mPa·s. It was purchased from Changzhou Yutong Rare Precious Metals Co., Ltd., item number 202307046. Hovenia dulcis powder 1: Particle size is 95% passing through an 80-mesh sieve, purchased from Xi'an Nuozhong Kangjian Biotechnology Co., Ltd., product number 20250715; Hovenia dulcis powder 2: Particle size is 95% passing through a 60-mesh sieve, purchased from Yangling Ruifen Biotechnology Co., Ltd., product number 20231230; Whey protein peptide 1: with an average molecular weight of 1500 Da, purchased from Zhongshiduqing (Shandong) Biotechnology Co., Ltd., product number 250114001; Whey protein peptide 2: average molecular weight 2500 Da, purchased from Hebei Heyixin Biotechnology Co., Ltd., product number 209531; Casein hydrolyzed peptide 1: 70% of the peptides have a relative molecular mass ≤10 kDa. It was purchased from Hangzhou Kangyuan, product number 20241226. Casein hydrolyzed peptide 2: The peptides with a relative molecular mass ≤10 kDa accounted for 100% of the total mass. It was purchased from Guangzhou Green Extract Biotechnology Co., Ltd., product number 20241230. Collagen peptide 1: with an average molecular weight of 2000 Da, purchased from Hubei Ruibang Biotechnology Co., Ltd., product number 240630; Collagen peptide 2: with an average molecular weight of 3600 Da, purchased from Beijing Shengmeinuo Biotechnology Co., Ltd., product number 20250412.

[0042] Examples 1-8 and Comparative Examples 1-7 The present invention provides a composition in the embodiments and comparative examples, the components (parts by mass) of the composition being shown in Table 1; Table 1 The composition provided in Example 1 is prepared by mixing the components evenly to obtain the composition.

[0043] The preparation methods of the compositions provided in Examples 2-8 and Comparative Examples 1-7 are consistent with those in Example 1; if the relevant components are not available, they can be omitted.

[0044] Example 9 This invention provides a composition, the only difference between the composition and Example 1 being that sodium carboxymethyl cellulose 2 is used instead of sodium carboxymethyl cellulose 1.

[0045] Example 10 This invention provides a composition, the only difference between the composition and Example 1 being that Hovenia dulcis powder 2 is used instead of Hovenia dulcis powder 1.

[0046] Example 11 This invention provides a composition, the only difference between the composition and Example 1 being whey protein peptide 2 instead of whey protein peptide 1.

[0047] Example 12 This invention provides a composition, the only difference between the composition and Example 1 being that casein hydrolyzed peptide 2 is used instead of casein hydrolyzed peptide 1.

[0048] Example 13 This invention provides a composition, the only difference between the composition and Example 1 being that collagen peptide 2 is used instead of collagen peptide 1.

[0049] Comparative Example 8 The present invention provides a composition in a comparative example, the only difference between the composition and Example 1 being that konjac powder (purchased from Hubei Yizhi Konjac Biotechnology Co., Ltd., item number 20240110) is used instead of sodium carboxymethyl cellulose 1.

[0050] Comparative Example 9 The present invention provides a composition in a comparative example, the only difference between the composition and Example 1 being that licorice powder (with a particle size of 95% passing through an 80-mesh sieve, purchased from Guangdong Qingyunshan Pharmaceutical Co., Ltd., item number 20240101) is used instead of Hovenia dulcis powder 1.

[0051] Comparative Example 10 The present invention provides a composition in a comparative example, the only difference between the composition and Example 1 being that soy peptides (average molecular weight of 1800 Da, purchased from Shanghai Lingyue Industrial Co., Ltd., item number 20250620) are used instead of whey protein peptide 1.

[0052] Comparative Example 11 The present invention provides a composition in a comparative example, the only difference between the composition and Example 1 being that wheat peptide (average molecular weight of 2000 Da, purchased from Zhejiang Nuoyan Biotechnology Co., Ltd., catalog number 230621) is used instead of casein hydrolyzed peptide 1.

[0053] Comparative Example 12 The present invention provides a composition in a comparative example, the only difference between the composition and Example 1 being that wheat peptide (average molecular weight of 2000 Da, purchased from Zhejiang Nuoyan Biotechnology Co., Ltd., catalog number 230621) is used instead of collagen peptide 1.

[0054] Example of effect The effectiveness examples of this invention verify the effects of the prepared composition, including the following aspects: 1. The ability to promote GLP-1 secretion includes the following steps: 1) Test samples: The compositions prepared in the examples and comparative examples were dissolved in STC-1 cell culture medium (ZM0714, purchased from Zhongqiao Xinzhou). The concentration of each group of samples was set to 1 mg / mL to obtain the test samples. 2) STC-1 mouse small intestinal endocrine cell line was seeded into 6-well plates. When the cell density reached 90%, the corresponding intervention was given according to the experimental groups. The experimental groups were blank control group (cell culture medium without test sample), positive control group (glucose + cell culture medium), and test sample group. 2 mL of liquid was added to each well of the 6-well plate. The concentration of glucose and test sample was 1 mg / mL. 3) After a period of intervention, aspirate the culture medium from each well, centrifuge at 10,000 rpm for 15 minutes, and detect GLP-1 by ELISA or freeze at -80℃; 4) Equilibrate the ELISA reagent to room temperature and set up blank wells, standard wells, and sample wells. Add the supernatant of cell culture medium after treatment of the blank control group, positive control group, and each sample group to the enzyme-labeled wells. Add 100 μL of sample dilution to the blank wells and add 100 μL of standard or sample to the remaining wells. Cover the enzyme-labeled wells with a membrane and incubate at 37°C for 90 min. 5) Discard the liquid, shake dry, add 100 μL of horseradish peroxidase (HRP) labeled detection antibody to each well, cover the enzyme-labeled wells with a membrane, and incubate at 37°C for 60 min. 6) Discard the liquid in the wells, shake dry, wash the plate three times with PBS, soaking for 1-2 minutes each time, about 350 μL / well, shake dry and blot dry with absorbent paper; 7) Add 100 μL of HRP working solution to each well, cover the enzyme-labeled wells with a membrane, and incubate at 37°C for 30 min; 8) Discard the liquid in the well, spin dry, and wash the plate 5 times; 9) Add 90 μL of substrate solution to each well, cover the enzyme-labeled wells with a membrane, and incubate at 37°C in the dark for 15 min; 10) Add 50 μL of stop solution to each well to terminate the reaction; 11) Immediately use an ELISA reader to detect the absorbance at a wavelength of 450nm. The formula for calculating the relative content of GLP-1 is: Relative content of GLP-1 = A sample group to be tested / A blank control group × 100%, where A sample group to be tested is the absorbance value of each treatment group, and A blank control group is the absorbance value of the blank control group. The reagents, consumables, and instruments used are as follows: Reagents: STC-1 mouse small intestinal endocrine cell line 25T, catalog number: ZQ0714, Zhongqiao Xinzhou; Glucagon-like peptide-1 (GLP-1) ELISA kit 96T, catalog number: H294-1-2, Nanjing Jiancheng; STC-1 mouse small intestinal endocrine cell line culture medium 125mL×4, catalog number: ZM0714, Zhongqiao Xinzhou; antibiotics, fetal bovine serum, phosphate-buffered saline (PBS) for cell culture, trypsin, CCK8 kit, etc. Instruments: CO2 incubator, multi-functional microplate reader, clean bench, microscope, centrifuge, pipette, etc.

[0055] The results are shown in Table 3.

[0056] 2. The inhibitory effect on DPP-4 enzyme activity includes the following steps: H-Gly-Pro-7-amido-4-methylcoumarin-hydrobromide (H-Gly-Pro-AMC) was used as the DPP-4 substrate, and sitagliptin was used as the positive control. Test samples: The compositions prepared in the examples and comparative examples were dissolved in PBS buffer, and each example and comparative example was prepared into a 0.5 mg / mL solution to obtain the test samples; the positive control sitagliptin was dissolved in PBS buffer to prepare a 100 nmol / L solution.

[0057] Grouping: negative control group (PBS buffer + DPP-4 + substrate), blank control group (PBS buffer + substrate), test sample group (test sample + DPP-4 + substrate), and blank sample group (test sample + PBS buffer + substrate). The reaction system for DDP-4 enzyme activity detection is shown in Table 2. Table 2 The kinetic analysis method of the microplate reader is as follows: an in vitro DPP-4 enzyme-catalyzed reaction system with a total volume of 150 μL, a reaction temperature of 37℃ and a pH of 8 was established. The group settings are shown in Table 2. After reacting at 37℃ for 2 hours, the absorbance value A at a wavelength of 405 nm was detected. The formula for calculating the inhibition rate of DPP-4 is: Inhibition rate = ((A negative control - A blank control) - (A test sample - A blank sample)) / (A negative control - A blank control) × 100%; Reagents, consumables, and instruments: 7-amino-4-methylcoumarin (batch number: 26093-31-2) and dimethyl sulfoxide (DMSO) (batch number: 20240315) were purchased from Beijing Solarbio Science & Technology Co., Ltd.; dipeptidyl peptidase-IV (DPP-4) (batch number: 10688-HNCH) and H-Gly-Pro-7-amido-4-methylcoumarin-hydrobromide (H-Gly-Pro-AMC) substrate (batch number: 20190617); sodium dihydrogen phosphate (batch number: 20191201) and disodium hydrogen phosphate (batch number: 20200302) were purchased from Tianjin Damao Reagent Factory; sitagliptin (batch number: J20140095) was purchased from Hangzhou Merck Pharmaceutical Co., Ltd. Instruments: constant temperature water bath, multi-functional microplate reader, centrifuge, pipette, etc.; The results are shown in Table 3.

[0058] 3. Satiety evaluation Ninety healthy volunteers were recruited and divided into nine groups of ten each. The actual satiety effects of Examples 1, 3-4, 7, Comparative Examples 1, 4, 7, and 9-10 were evaluated. The satiety test evaluation method followed the group standard "T / CNSS 019 Food Satiety Test Specification". The satiety of a reference food was tested in all nine groups as baseline data. The time interval between consuming the reference food and consuming the test sample was 48 hours. The reference food was 60g of white bread. The test sample was consumed within the first 3 minutes of consuming the 60g white bread, followed by an additional 5g of the test sample. Both the sample and the white bread were to be consumed within 15 minutes. The time before consuming the sample or white bread was recorded as 0 hours (fasting). The rate of change in satiety compared to the reference food was measured within 4 hours after consuming the test sample and white bread. The results are shown in Table 3, where ND indicates that no relevant test was performed. Specifically, firstly, the satiety curve of the reference food within 0-4 hours is tested, and the area under the satiety curve of the reference food is calculated. Then, the satiety curve of the sample plus the reference food within 0-4 hours is tested, and the area under the satiety curve of the sample plus the reference food is calculated. Next, the rate of change of satiety is calculated as follows: rate of change of satiety = (area under the satiety curve of the sample plus the reference food - area under the satiety curve of the reference food) / area under the satiety curve of the reference food.

[0059] Table 3 As can be seen from Table 3, when using the technical solution provided by the present invention, the obtained product has excellent effects in promoting GLP-1 secretion, inhibiting DPP-4 enzyme activity, and good satiety effect in human trials; specifically, the relative content of GLP-1 in the obtained product is above 211%, the DPP-4 enzyme activity inhibition rate is above 18.75%, and the satiety change rate 4 hours after ingesting the test sample is above 62.4%. As can be seen from Examples 1-3 and Comparative Example 7, the mass fraction of the components affects the overall performance of the composition. When the mass fraction of the components in Comparative Example 7 is outside the range given in this invention, the proportion of the composition that promotes GLP-1 secretion decreases significantly, the inhibition rate of DPP-4 enzyme activity also decreases significantly, and the rate of change in satiety 4 hours after ingestion of the test sample also decreases significantly. As can be seen from Examples 1 and Comparative Examples 1-6, the components in this invention have a good synergistic effect. When one or any two of them are missing, the effect of the product on promoting GLP-1 secretion and the inhibition effect on DPP-4 enzyme activity decreases significantly, and the rate of change in satiety 4 hours after ingestion of the test sample also decreases significantly. It can be seen that the composition of this invention achieves better satiety by physically filling the stomach and synergistically regulating appetite hormones such as GLP-1 and DPP-4.

[0060] As can be seen from Examples 1 and 4-8, the type of peptide also affects the overall performance of the product. When the peptides are further selected to include whey protein peptides, casein hydrolysate peptides and collagen peptides, and the mass ratio of the three is within the preferred range of the present invention, the resulting product has a better effect on promoting GLP-1 secretion, a higher DPP-4 inhibition rate, and a stronger feeling of satiety. As can be seen from Example 1 and Comparative Examples 8-12, when other similar components are used to replace the components of the present invention, the resulting products have a significantly weaker GLP-1 secretion-promoting effect, a lower DPP-4 inhibition rate, and a weaker feeling of satiety.

[0061] During the satiety test, the incidence of gastrointestinal discomfort among volunteers was simultaneously recorded. Only when taking the product prepared in Comparative Example 4 did two volunteers report gastrointestinal discomfort; no volunteers in the other groups reported any. This may be because the product in Comparative Example 4 only exerted a certain satiety effect through the gastric space-occupying effect of sodium carboxymethyl cellulose, which could cause significant gastrointestinal irritation for some volunteers with weaker gastrointestinal function. The other groups were additionally fortified with peptides and / or Hovenia dulcis seeds. The peptides contain glutamine and proline, which can help repair atrophic gastritis and intestinal barrier damage. Hovenia dulcis seeds are a well-known liver-protecting ingredient and may have an indirect regulatory effect on gastrointestinal discomfort associated with poor liver function.

[0062] Finally, it should be noted that the above embodiments are used to illustrate the technical solutions of the present invention and not to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. A composition for controlling appetite and enhancing satiety, characterized in that, The composition comprises the following components in parts by weight: 10-30 parts sodium carboxymethyl cellulose, 4-15 parts polypeptide, 1-5 parts Japanese raisin tree powder; The polypeptides are whey protein peptides, casein hydrolysate peptides, and collagen peptides.

2. The composition according to claim 1, characterized in that, The composition comprises the following components in parts by weight: 15-25 parts sodium carboxymethyl cellulose, 8-12 parts polypeptide, and 2-4 parts Hovenia dulcis powder.

3. The composition according to claim 1, characterized in that, The mass ratio of whey protein peptides, casein hydrolysate peptides, and collagen peptides is 1:(0.2-0.8):(0.2-0.8).

4. The composition according to claim 3, characterized in that, The mass ratio of whey protein peptides, casein hydrolysate peptides, and collagen peptides is 1:(0.6-0.8):(0.6-0.8).

5. The composition according to claim 1, characterized in that, The viscosity of a 1 wt% aqueous solution of sodium carboxymethyl cellulose is 1200-2400 mPa·s.

6. The composition according to claim 1, characterized in that, The particle size of the Hovenia dulcis powder is 95%-100% passing through an 80-mesh sieve.

7. The composition according to claim 1, characterized in that, The average molecular weight of the whey protein peptides is 500-2000 Da.

8. The composition according to claim 1, characterized in that, The proportion of peptides with a relative molecular mass ≤10 kDa in the casein hydrolysate peptides is 65%-90%.

9. The composition according to claim 1, characterized in that, The average molecular weight of the collagen peptides is 800-3000 Da.

Images